MEDSNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
DataMeds AI, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026
$2.67+0.04 (+1.52%)
Close on Oct 19, 2026
- Market cap
- $6.87M
- P/E (TTM)
- –
- Dividend yield
- –
DataMeds AI, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $3.94M | $11.43M | $21.87M | $33.04M | $35.89M | – | $17.67M | 49.2% | -89.0% |
| Pharmacy Retail Sales [Member] | $3.40M | $1.89M | $865.70K | $528.19K | $500.26K | $467.04K | $352.36K | 42.4% | +579.3% |
| Third Party Logistics Services [Member] | $680.64K | $722.42K | $603.42K | $509.55K | $351.99K | – | $107.00K | 8.5% | +93.4% |
By region
From the segment and revenue-disaggregation notes of DataMeds AI's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.